降血糖藥物SGLT2抑制劑之開發

Antidiabetic Agent - The Development of SGLT2 Inhibitors

李靜琪(Jinq-Chyi Lee)

《化學》 74卷2期 (2016/06) Pp. 147-158

https://doi.org/10.6623/chem.2016012

摘要

藉由抑制腎臟對已過濾葡萄糖的再吸收，從而增加尿液中葡萄糖的排出量，進而達到控制血糖濃度的SGLT2 (sodium-dependent glucose co-transporter 2)抑制劑是與胰島素作用無關的新機轉藥物，不論是單一或合併其他降血糖藥物使用，都有良好控制血糖的效果，同時具有體重減輕、降低血壓及低低血糖風險等附加優點，為第二型糖尿病患者提供了另一種治療選擇，只是仍必須進行長期的追蹤以釐清目前在安全上的疑慮。本篇文章主要就SGLT2抑制劑的研究與發展做一個簡要的介紹。

關鍵字

SGLT2抑制劑 ； 第二型糖尿病

並列摘要

Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) with a novel insulin-independent action are a promising new therapeutic option for the treatment of type 2 diabetes by suppressing the reabsorption of filtered glucose in the kidney, which leads to urinary glucose excretion and hence reduces the plasma glucose concentration. In addition to the therapeutic benefit in attaining glycemic control, low risk of hypoglycemia and reduction in weight and blood pressure make SGLT2 inhibitors more unique; however, long-term follow-up of patients was recommended due to the unexpected side-effects. Herein, the development of SGLT2 inhibitors is briefly summarized in this article.

並列關鍵字

SGLT2 inhibitors ； Type 2 diabetes